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(SOC) vs SOC alone in the US health care setting. The objective of this analysis is to 
assess the cost-effectiveness of RDN in patients with TR-HTN from the Australian 
payer perspective. Methods: Geisler methods were largely retained but life tables, 
resource use, costs and discount rates were revised to reflect Australian parameters. 
Importantly, the treatment effect of RDN was based on a meta-analysis of all studies 
(regardless of catheter used) enrolling TR-HTN patients (SBP ≥ 160 mmHg despite 
> 3 anti-hypertensive drugs including a diuretic). The model consisted of 30 health 
states and employed multivariate risk equations from large-scale cohort studies 
to calculate transition probabilities of events and event mortality. Discounted (5%) 
costs and outcomes were calculated over a lifetime horizon. Results: The weighted 
mean decrease in office-based SBP over 6 months was -28.1 mmHg (95% CI: -24.5 
to -31.6). The RDN procedure cost ($10,724.22) was partially offset by lower event 
costs – primarily through a reduced incidence of stroke (-0.0559) and MI (-0.0524). 
RDN was associated with higher incremental costs ($5,951.04) and additional QALYs 
(0.4296) resulting in an incremental cost per QALY of $13,852. Sensitivity analyses 
demonstrated reliability of the base case results across a wide range of assump-
tions. ConClusions: Consideration of both clinical and economic evaluations may 
be necessary to inform reimbursement decision making. Based upon this analy-
sis, RDN is a cost effective treatment option for patients with rHTN in Australia. 
However, this conclusion is dependent upon the magnitude of SBP reduction with 
RDN and assumptions related to long term patient outcomes.
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objeCtives: Hypertension represents a major health problem, affecting more 
than 21% of adults in the Philippines. Amlodipine, a calcium channel blocker, is 
considered to have better tolerance and effectiveness than other classes of anti-
hypertensive treatments. Limited studies have examined the cost-effectiveness of 
Amlodipine in the Philippines. The purpose of this study was to compare the costs 
and effectiveness associated with Amlodipine and Angiotensin II Receptor Blockers 
(Valsartan) in preventing stroke and myocardial infarction (MI) among Filipino 
hypertension patients. Methods: A Markov model was developed using effec-
tiveness, rate of stroke and MI, survival and utility data from published literature. 
Costs of drugs, direct medical costs of hypertension management, stroke/MI treat-
ment, and follow-up management were included. Costs were based on a survey on 
experts in the Philippines except costs of MI treatments, which was retrieved from 
the literature. Total costs and QALYs in a five-year time horizon were calculated and 
compared between Amlodipine and Valsartan. The modeling was conducted with 
10,000 hypertension patients in the Amlodipine and Valsartan arms respectively. 
Discounting rate used for costs and QALYs was 3%. Third-party payer perspective 
was adopted. Results: In the base case analysis, Amlodipine was more effective 
with 30,648.5 QALYs versus Valsartan group’s QALYs which were 30,520.8 (net gain 
was 127.8 QALYs). Amlodipine was less costly with PHP766,083,016 while Valsartan 
group’s costs were PHP2,076,035,008 (costs saved were PHP1,309,951,992). Total cost 
was more sensitive than total QALYs to the sensitivity tests. Changing discount 
rate and cohort age had greater effect on the total cost and QALYs than changing 
the other parameters. However, Amlodipine remained dominant in the different 
scenarios of sensitivity analyses. ConClusions: This modeling analysis suggests 
that Amlodipine achieved overall cost saving and better outcomes when compared 
with ARBs (Valsartan) for hypertension patients in the Philippines.
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objeCtives: Warfarin, the standard oral anticoagulant for stroke prevention in 
patients with atrial fibrillation (AF), is associated with frequent international normal-
ized ratio (INR) monitoring and increased hemorrhagic risk. About 50% of European 
and American AF patients received warfarin nevertheless. Dabigatran, a novel oral 
anticoagulant, had been compared to warfarin to demonstrate its cost-effectiveness 
in developed countries. However, these economic evaluations couldn’t be applied to 
China setting. Despite treatment guidelines, warfarin use was conservative in China 
accounting for only 2.7% AF patients. More than half of the patients (56%) received 
aspirin, and still another 33% did not receive any prophylaxis therapy. In this study, we 
aimed to evaluate the cost-effectiveness of dabigatran in China settings and highlight 
the importance of setting up the right analysis scenarios. Methods: An individual-
level simulation model was developed to project the clinical events and outcomes 
under different treatment pathways over a patient’s remaining lifetime. Three sce-
narios were evaluated. First, aspirin, warfarin, and dabigatran were eligible first-line 
options over no treatment. Second, due to reluctance in warfarin use, only aspirin 
and dabigatran were considered. Third, reluctance in warfarin use together with con-
traindication to aspirin leaved dabigatran the only option. Efficacy/safety data were 
derived from RE-LY trial and published meta-analyses and literature. China-specific 
data were from published studies and expert inputs. Results: In scenario 1, warfarin 
was cost-saving comparing to no-treatment and the ICER for dabigatran versus war-
farin was CNY 367425.7/QALY. Aspirin was dominated. In scenario 2, aspirin was cost-
saving comparing to no-treatment and the ICER for dabigatran versus aspirin was 
CNY 253592.3/QALY. In scenario 3, the ICER for dabigatran versus no-treatment was 
CNY 85436.2/QALY. Given a WTP of CNY 115,261/QALY, conclusions on dabigatran’s 
cost-effectiveness varied in three scenarios. ConClusions: The cost-effectiveness 
of an intervention is not absolute. Country heterogeneity demands careful considera-
tions when setting up the scenarios for analyses.
medical costs of hypertension management, stroke/MI treatment, and follow-up man-
agement were included. All costs inputs were based on either published literature or 
an expert survey. Utility data were retrieved from published literature. Discounting 
rate used for both costs and QALYs was 3% and currency reported in 2014 US dollar 
(US$1 = 30 Taiwanese dollar). Third-party payer perspective was applied. Results: 
Based on the hypothetical cohort of 10,000 hypertension patients, total costs for 
amlodipine and valsartan users were US$7,969,402 and US$13,169,296 respectively. 
Total QALYs was 30,648.5 for amlodipine users and 30,520.8 for valsartan users. 
Compared to valsartan, amlodipine had an incremental cost of -US$5,199,894 with 
127.7 QALYs gained. Results remained consistent from various sensitivity analy-
ses. ConClusions: For hypertension patients in Taiwan, amolodipine is a cost-
saving treatment with better outcomes in preventing stroke and MI in comparison 
with valsartan. It lowers the acute care costs associated with stroke and MI as well 
as costs of follow-up disease management.
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objeCtives: Dyslipidemia is a common chronic disease in China, which is a main 
risk factor for cardiovascular and cerebrovascular diseases. Blood lipid screening is 
a positive method for prevention of dyslipidemia, but the cost-effectiveness of blood 
lipid screening is still unknown. The objective of this study aims to evaluate the cost-
effectiveness of blood lipid screening versus no screening for the primary prevention 
of hyperlipidemia and its complication. Methods: A Markov model was designed 
according to dyslipidemia clinical development and pathway for the cost-effective-
ness analysis. Markov model simulated the long term effects of screening and no 
screening strategies. The model assumed the starting age of 45 and a 30 year horizon. 
All the data for Markov model were extracted from literatures published. The costs 
and benefits were both discounted at 5%. Sensitivity analyses were adopted to explore 
assumptions of the model and to identify which model inputs had most impact 
on the results. Results: The model results showed that the per capita cumulative 
costs and utilities in no screening group were CNY65343 and 12.58 QALYs, and CNY 
64337 and 12.9 QALYs in screening group. Comparing with the no screening group, 
the screening had lower costs and higher utility. The results of One-way sensitivity 
analysis showed that the transition probability from dyslipidemia (no screening) to 
complications, the transition probability from dyslipidemia (screening detected) to 
complications and the cost of drug intervention had obvious impacts on the model 
results. ConClusions: Based on this Markov model, blood lipid screening is likely 
to be cost-effective compared with no screening for the primary prevention of dys-
lipidemia and its complication among Chinese aged 45 and above.
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objeCtives: To determine the cost-effectiveness of catheter-based renal dener-
vation (RDN) for resistant hypertension over a lifetime from the National Health 
Insurance perspective in Korea. Methods: We adopted a Markov state-transition 
model with a monthly cycle which has been developed and validated recently to 
assess clinical and economic impact of replacing ‘standard of care (SOC) alone’ with 
‘SOC plus RDN.’ The model was calibrated to predict the cost-effectiveness of RDN 
in Korean health care setting by best utilizing Korea-specific data for key model 
parameters. Our analysis was based on the Symplicity HTN-2 trial for the changes 
in systolic blood pressure (SBP) at 6 months after RDN treatment. The model incor-
porates 7 clinical endpoints associated with hypertension: hypertension (referring 
to no event), angina pectoris, myocardial infarction, stroke, heart failure, end-stage 
renal diseases, and cardiovascular and non-cardiovascular death (absorbing state). 
A total of 34 health states were defined reflecting all possible health states associ-
ated with the clinical endpoints based on the natural history of diseases. Results: 
According to the base-case analysis, each subject receiving SOC plus RDN to treat 
resistant hypertension gained 0.37 QALYs and 7.21 million Korean won (KRW, one 
US dollar = 1,100 KRW) more than a subject with SOC alone. The incremental cost-
utility ratio (ICUR) was 19.69 million KRW per QALY gained. The results of sensitiv-
ity analyses showed that the relative cost-effectiveness was most sensitive to the 
SBP lowering effect of RDN. Other variables had only minimal impact on results, 
supporting the robustness of the results. ConClusions: ‘SOC plus RDN’ appears 
to be a cost-effective treatment option for patients with resistant hypertension in 
Korea based on the WHO recommendation that a treatment is very cost-effective 
if the treatment’s ICUR is lower than the gross domestic product (GDP) per capita. 
The per-capita GDP in Korea in 2012 was 26 million KRW.
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objeCtives: Catheter-based renal denervation (RDN) is an effective and durable 
therapy option for patients with treatment resistant hypertension (TR-HTN). Based 
on results of the Symplicity HTN-2 trial (NCT00888433), Geisler et al. (2012) devel-
oped a Markov model to quantify the cost effectiveness of RDN plus standard of care 
